The Orbit Display Bead:
Peptide and Encoding DNA: Linked
Orbit CEO, Neil Butt, and Simon Bushell (Business Development) will be attending Bio Europe Spring in Milan, Italy from March 17th-19th.
Oxford, UK, and Springfield, NJ, USA, 3rd December 2024: – Orbit Discovery, a leading provider of peptide discovery services, and Evergreen Theragnostics, a radiopharmaceutical company at the forefront of precision medicine, today announced an extension to their research collaboration to find novel targeting peptides for radiopharmaceutical delivery. This collaboration expands upon a previous agreement signed between Orbit and Evergreen the companies in April 2023 whereby technology synergies have enabled the identification of high-affinity peptide ligands optimized for precision therapeutic applications.
Orbit CEO Neil Butt and Business Developer Simon Bushell will be the 2024 BioEurope conference in Stockholm, Sweden from November 4-6th, 2024. They would be delighted to talk about how our platforms empower big pharma and small biotech alike in their peptide discovery efforts.